Understand the source comparison
Selank Amidate Results Timeline: Administration Method Comparison
The following table compares how administration variables influence the Selank Amidate results timeline across the three primary phases. Intranasal 300 mcg twice daily 20–40 minutes Day 10–12 Week 3–4 Fastest onset, highest compliance, standard research protoc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares how administration variables influence the Selank Amidate results timeline across the three primary phases.
- Intranasal 300 mcg twice daily
- 20–40 minutes
- Day 10–12
- Week 3–4
- Fastest onset, highest compliance, standard research protocol
- Optimal for most research applications requiring rapid anxiolytic response
- Intranasal 600 mcg twice daily
- 15–30 minutes
- Day 5–7
- Week 3
- Accelerated Phase 2, higher side effect risk (nasal irritation)
- Best for protocols prioritizing cognitive enhancement over pure anxiolysis
- Subcutaneous 500 mcg once daily
- 60–90 minutes
- Day 12–14
- Week 4
- Slower onset, fewer daily administrations, more stable plasma levels
- Useful for protocols where acute onset is less critical than sustained effect
- Subcutaneous 1000 mcg once daily
- 45–75 minutes
- Day 8–10
- Comparable to intranasal 600 mcg twice daily, single administration
- Reduces administration frequency without sacrificing Phase 2/3 timelines
- Interpretation Note: The timelines above assume daily administration without missed doses. Skipping administrations during the first two weeks delays BDNF-mediated neuroplasticity proportionally. Missing 3 days in week 2 pushes Phase 2 onset from day 10 to approximately day 13.